A 34-year-old woman with poorly controlled type 2 diabetes presents with vulvovaginal itching, erythema, and thick white vaginal discharge. Wet mount microscopy shows budding yeast and pseudohyphae. She has no fever and is otherwise stable. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Assessment This patient presents with uncomplicated vulvovaginal candidiasis (VVC) — a localized mucosal infection caused by *Candida albicans*. The diagnosis is confirmed by wet mount microscopy showing budding yeast and pseudohyphae. **Key Point:** Uncomplicated VVC in an immunocompetent host (no systemic signs, no fever, no immunosuppression) is treated with topical or oral antifungals as outpatient therapy. ## Management Algorithm for Vulvovaginal Candidiasis ```mermaid flowchart TD A[Vulvovaginal candidiasis suspected]:::outcome --> B{Systemic signs or immunocompromised?}:::decision B -->|No fever, immunocompetent| C[Uncomplicated VVC]:::outcome B -->|Fever, sepsis, immunosuppressed| D[Invasive candidiasis]:::urgent C --> E[Oral fluconazole 150 mg single dose<br/>OR topical azole]:::action D --> F[Blood culture + IV antifungal<br/>Caspofungin or amphotericin B]:::action E --> G[Outpatient follow-up]:::outcome F --> H[ICU/HDU monitoring]:::outcome ``` ## Treatment Options for Uncomplicated VVC | Agent | Dose | Route | Efficacy | | --- | --- | --- | --- | | **Fluconazole** | 150 mg | Oral, single dose | 90% cure rate; first-line | | Clotrimazole | 100 mg | Vaginal tablet × 6 nights | Topical alternative | | Miconazole | 2% cream | Topical × 7 days | Topical alternative | | Itraconazole | 200 mg BD | Oral × 1 day | Alternative if fluconazole unavailable | **High-Yield:** Oral fluconazole 150 mg single dose is the gold standard for uncomplicated VVC — high efficacy, convenient, and well-tolerated. [cite:Harrison 21e Ch 211] **Clinical Pearl:** The presence of poorly controlled diabetes increases *Candida* colonization due to elevated glucose in vaginal secretions, but does not convert this to invasive disease unless there are systemic signs (fever, hemodynamic instability, or immunosuppression). ## Why This Patient Does NOT Need Systemic Therapy **Key Point:** Indicators of invasive candidiasis (requiring IV antifungals) include: - Fever and sepsis - Neutropenia or severe immunosuppression - Positive blood cultures - Disseminated symptoms (hepatosplenomegaly, retinal lesions) This patient has NONE of these — she is afebrile, stable, and has localized vaginal symptoms only.